Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2019-08-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于首次公开发行募集资金项目结项及节余募集资金永久性补充流动资金并注销募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the completion of a fundraising project related to its initial public offering (IPO) and the permanent allocation of surplus raised funds to supplement working capital. It details the amount of funds raised, their usage, surplus funds, and the approval process involving the board, supervisory committee, independent directors, and the sponsor institution. The document references regulatory compliance with stock exchange listing rules and company law. It is not a full financial report but an announcement about the status and use of raised capital funds. The document length is about 5912 characters, which is substantial but the content is focused on fundraising project completion and fund allocation rather than comprehensive financial statements or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2019-08-27 Chinese
2019年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2019 年半年度报告摘要" which translates to "2019 Semi-Annual Report Summary." It contains detailed financial data for the half-year period, including revenue, net profit, cash flow, earnings per share, and asset information. It also discusses company operations, management decisions, R&D activities, and changes in accounting policies. The length of the document (10,580 characters) and the presence of substantive financial data and analysis confirm it is a financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-08-27 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by the company 健帆生物科技集团股份有限公司. It details the reasons for the change, the specific accounting policy changes, the approval process by the board and supervisory committee, and opinions from independent directors and the supervisory board. The document references regulatory requirements from the Ministry of Finance and the Shenzhen Stock Exchange. The document length is 2502 characters, which is relatively short and primarily serves as a formal announcement of the accounting policy change rather than a full financial report. It does not contain actual financial statements or detailed financial data but rather explains the policy change and its impact. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about accounting policy changes without substantive financial data or a full report attached.
2019-08-27 Chinese
2019年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2019 Half-Year Special Report on the Deposit and Actual Use of Raised Funds" by the company. It details the amount of funds raised, their deposit in special accounts, usage status, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and disclosure of raised funds. It includes detailed tables of funds usage, bank accounts holding the funds, and explanations about project delays and cash management. The document is a specialized report focusing on the management and use of capital raised by the company, not a general financial report or earnings release. It is not an announcement of a report publication but the report itself. This type of document fits the category of Capital/Financing Update (CAP), as it provides updates on the company's fundraising and the use of those funds.
2019-08-27 Chinese
中航证券有限公司关于公司首次公开发行募集资金项目结项及节余募集资金永久性补充流动资金并注销募集资金专户的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the completion and use of funds raised from an initial public offering (IPO) by a company. It discusses the amount of funds raised, their management, usage, surplus funds, and the plan to permanently supplement working capital with the surplus. It includes approvals from the board, supervisory committee, independent directors, and the sponsoring institution's verification opinion. The document references regulatory rules and compliance with stock exchange listing rules. It is not a full annual or interim financial report, nor an earnings release or call transcript. It is a formal audit or verification report related to the use of IPO proceeds and compliance with regulations, which fits the category of an Audit Report / Information (AR). The document length is over 6,000 characters and contains substantive content, not just an announcement or certification letter, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is AR (Audit Report / Information). H1 2019
2019-08-27 Chinese
关于召开2019年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2019 third extraordinary general meeting of shareholders for the company 健帆生物科技集团股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be voted on, registration details, and proxy forms. There is no financial data or report content; rather, it is an announcement and procedural guide for the shareholders' meeting. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. The document is not a report itself, nor is it a voting result announcement or a simple meeting notice. Therefore, the best classification is PSI.
2019-08-27 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.